

Nexus Surgical and Medicare Limited
(Formerly known as Nexus Commodities and Technologies Limited)

CIN - L33100MH1992PLC328367

Registered Office Gala No 4, Saarthak, Building No 1, Square Industrial Park,
Tungarphata, Vasai (East), Palghar - 401 208

Email nexuscomm92@gmail.com Tel. No. +91 8433598185

Website www.nexusmed.co.in

Date 13th November, 2021

To,
BSE Limited
Corporate Relation Department,
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai - 400 001

Script Code - 538874

Sub. Outcome of Board Meeting held on Saturday, 13th November, 2021

Dear Sir / Madam,

We would like to inform you that the meeting of the Board of Directors of **Nexus Surgical and Medicare Limited** was held on **Saturday, 13th November, 2021 at 03.30 p m** at the Registered Office of the Company situated at Gala No 4, Saarthak, Building No 1, Square Industrial Park, Tungarphata, Vasai (East), Palghar - 401 208 and transacted the following business

- 1 The Board of Directors of the Company has approved the unaudited quarterly financial results of the Company for the quarter and half year ended 30th September, 2021. A copy of the same alongwith Limited Review Report on the said results is enclosed herewith for your kind perusal,
- 2 The Board of Directors of the Company took on record the resignation of Ms Khyati Girishkumar Bhatt (holding DIN 05317955), Independent Director of the Company, with effect from the close of business hours of 1st November, 2021

The meeting commenced at 03 30 p m and concluded at 04 00 p m


Kindly take the same on your records

Thanking you

Yours faithfully,

For Nexus Surgical and Medicare Limited

(Formerly known as Nexus Commodities and Technologies Limited)


Ram Swaroop Joshi
DIN: 07184085
Whole-time Director



Encl as above

Nexus Surgical and Medicare Limited
(Formerly known as Nexus Commodities and Technologies Limited)
Statement of Unaudited Financial Results for the Quarter and Half Year ended September 30, 2021

(Rs in lakhs except equity per share data)

Particulars	Quarter ended on			Half Year Ended on		Year ended
	Sep 30, 2021 (Unaudited)	June 30, 2021 (Unaudited)	Sep 30, 2020 (Unaudited)	Sep 30, 2021 (Unaudited)	Sep 30, 2020 (Unaudited)	March 31, 2021 (Audited)
Income						
Sales and Services	40 00	23 00	135 26	63 00	336 42	374 42
Other Income	0 12	0 61	0 18	0 73	0 18	0 84
Total Income	40 12	23 61	135 44	63 73	336 61	375 27
Expenses						
Purchase of stock in trade (net of return)			9 83		102 47	102 47
Change in inventories of stock in trade						
Employee benefits expense	4 32	7 50	8 40	11 82	11 80	31 90
Depreciation and amortization expense	0 07	0 07	0 07	0 13	0 13	0 26
Other expense	15 57	0 84	92 81	16 42	146 90	223 59
Total Expenses	19 96	8 41	111 11	28 37	261 31	358 23
Profit/(loss) before Exceptional Item and Tax	20 16	15 20	24 33	35 36	75 30	17 04
Exceptional Item Income/(Loss)						
Profit/(loss) before Tax	20 16	15 20	24 33	35 36	75 30	17 04
Tax expenses	(1 14)	2 63	6 12	1 49	18 95	1 64
Profit/(loss) for the period	21 30	12 57	18 21	33 87	56 35	15 40
Other comprehensive income (OCI), net of income tax						
Items that will not be reclassified to profit or loss						
Items that will be reclassified to profit or loss						
Total other comprehensive income net of income tax						
Total other comprehensive Income for the period	21 30	12 57	18 21	33 87	56 35	15 40
Paid up Equity Share Capital (Equity shares of Rs 10 each)	547 19	547 19	547 19	547 19	547 19	547 19
Other Equity						(557 99)
Basic and Diluted Earning Per Share (not annualized)	0 39	0 23	0 33	0 62	1 03	0 28


Notes

- The above Financial result were reviewed by the audit committee thereafter approved and taken on record by the Board of Directors at their meeting held on November 13 2021
- The above results are audited by the Statutory Auditor of the Company
- The Company is engaged primarily in the trading business and accordingly there are no separate reportable segments as per Ind AS 108 dealing with Operating Segment
- The company has not received any shareholder / investors complaints during the quarter ended September 30 2021
- The figures for the corresponding previous period have been regrouped/ reclassified wherever necessary to make them comparable



Nexus Surgical and Medicare Limited
(Formerly known as Nexus Commodities and Technologies Limited)
Note 6 Statement of Assets and Liabilities

Particulars	<i>(Rs in lakhs)</i>	
	As at September 30, 2021 (Unaudited)	As at March 31, 2021 (Audited)
ASSETS		
Non current assets		
(a) Property, Plant and Equipment	1 62	1 64
(b) Income Tax Assets (Net)	12 91	9 42
(c) Deferred Tax Assets (Net)	1 03	1 15
Current assets		
(a) Financial Assets		
(i) Trade receivables		12 10
(iii) Cash and cash equivalents	6 21	21 95
(b) Loans and Advances	18 00	42 50
(c) Others	4 38	4 73
Total Assets	44 14	93 50
EQUITY AND LIABILITIES		
Equity		
(a) Equity Share capital	547 19	547 19
(b) Other Equity	(524 12)	(557 99)
LIABILITIES		
Current liabilities		
(a) Financial Liabilities		
(i) Borrowings		
(ii) Trade payables	20 25	100 42
(b) Other current liabilities	0 82	3 87
Total Equity and Liabilities	44 14	93 50





Nexus Surgical and Medicare Limited
(Formerly known as Nexus Commodities and Technologies Limited)
Note 7 Statement of Cash Flow

(Rs in lakhs)

Particulars	For the period ended	
	September 30, 2021	September 30, 2020
Profit before tax	35 36	75 30
Adjustment to reconcile net profit to net cash provided by operating activities		
Depreciation expenses	0 13	0 13
Interest & dividend Income	-	0 18
	<u>35 49</u>	<u>75 62</u>
Change in assets & liabilities		
Trade receivables	12 10	-
Income Tax Assets	(4 85)	(10 63)
Loans	-	(68 67)
Other Assets	24 85	(1 42)
Trade payables	(80 17)	4 23
Other financial & other liabilities	(3 06)	20 20
Cash generated from operating activities	<u>(15 63)</u>	<u>19 33</u>
Income Tax Paid		18 95
Net Cash generated from operating activities	<u>(15 63)</u>	<u>0 38</u>
Cash flow from investing activities		
Interest Income	-	(0 18)
Cash paid for acquiring fixed assets	(0 11)	-
	<u>(0 11)</u>	<u>(0 18)</u>
Cash flow from financing activities		
Borrowings	-	-
Interest Expenses	-	-
	<u>-</u>	<u>-</u>
Net cash generated	<u>(15 75)</u>	<u>0 20</u>
Cash & cash equivalents at the beginning of the year	21 95	2 09
Cash & cash equivalents at the end of the year	6 21	2 29
Reconciliation of cash and cash equivalents as per the cash flow statement		
Cash and cash equivalents as per above comprise of the following		
	September 30, 2021	September 30, 2020
Cash and cash equivalents	6 21	2 29
Balances per statement of cash flows	6 21	2 29

For and on behalf of Board of Directors of
Nexus Surgical and Medicare Limited


Ram Swaroop Joshi
Director
DIN 07184085



November 13 2021



Limited Review Report

Review Report to
The Board of Directors
Nexus Surgical and Medicare Limited

We have reviewed the accompanying Statement of unaudited standalone financial results **Nexus Surgical and Medicare Limited (Formerly known as Nexus Commodities and Technologies Limited)**, for the quarter and half year ended September 30, 2021, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, "Interim Financial Reporting" ("Ind AS 34"), prescribed under section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For and on behalf of
Satya Prakash Natani & Co.
Chartered Accountants
Firm's Registration No.: 115438W

Satya Prakash Natani
Partner
Membership No.: 048091
Mumbai
November 13, 2021
UDIN: **21048091AAAAHD1366**